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Introduction {#sec1}
============

Patients with type 1 diabetes suffer from a severe deficiency in insulin production by pancreatic islets as a result of immune-mediated destruction of pancreatic β cells. Insulin independence can be achieved by transplantation of cadaveric human islets ([@bib39]), but because of the scarcity of donor tissue, the field is exploring the potential use of scalable human embryonic stem cell (hESC)-derived pancreatic cells as an alternative cell source. We have demonstrated previously that hESC-derived pancreatic progenitor cells develop over several months in vivo into insulin-secreting cells capable of reversing hyperglycemia in a mouse model of type 1 diabetes ([@bib33], [@bib34], [@bib4]). Interestingly, the maturation process was accelerated when mice were exposed to chronic hyperglycemia but unaffected by exposure to long-term insulin therapy, short-term exendin-4 treatment, oral anti-diabetic medications, or high-fat diets ([@bib4], [@bib5]). In addition, we recently reported a revised differentiation protocol that generated glucose-responsive insulin-secreting cells in vitro and required a much shorter maturation period (∼6 weeks) following transplantation to reverse hyperglycemia in mice ([@bib35]). Given the uncertainty surrounding the complex host environment and variables that may affect the maturation process in vivo, advancing the differentiation protocols in vitro prior to transplantation may be advantageous. Nevertheless, hESC-derived pancreatic progenitor cells are currently being tested for safety, tolerability, and efficacy in a phase 1/2 clinical trial by Viacyte ([ClinicalTrials.gov](http://ClinicalTrials.gov){#intref0010} identifier NCT02239354). Therefore, although newer differentiation protocols have been reported ([@bib30], [@bib35], [@bib37]), it remains important to understand the development of pancreatic progenitor cells in vivo because clinical trials are underway in patients with diabetes.

There are several obvious differences between the pre-clinical transplant recipients tested to date (immunodeficient mice) and the target patient population, including the species, distinct metabolic profiles, and large size difference. Although rats are not directly comparable with humans, their physiology is reportedly more similar to humans than mice, particularly in terms of cardiovascular parameters ([@bib9]). We have demonstrated previously that hESC-derived grafts were capable of robust glucose-stimulated insulin secretion (GSIS) after just 14 weeks in nude rats, whereas GSIS was not observed until after 30 weeks in similar studies with severe combined immunodeficiency (SCID)-beige mice ([@bib33]). However, these studies were performed at different facilities and with different batches of cells, so we could not make direct comparisons between species. Interestingly, others have reported that hESC-derived pancreatic progenitor cells did not efficiently differentiate into pancreatic endocrine tissue following transplantation in nude rats ([@bib26]). The authors speculated that the nude rat may be a less accommodating host environment compared with immunodeficient mice ([@bib26]). To address these conflicting observations, we performed a carefully controlled study within a single research facility to directly compare the in vivo development of hESC-derived pancreatic progenitor cells from the same preparation and transplanted in parallel into either immunodeficient nude rats or SCID-beige mice.

Results {#sec2}
=======

hESC-Derived Insulin-Producing Cells Develop Faster and Function Better in Rats Than in Mice {#sec2.1}
--------------------------------------------------------------------------------------------

Pluripotent H1 cells were differentiated into pancreatic progenitor cells over 14 days, resulting in a population containing 17% endocrine cells (synaptophysin+). Chromogranin+ endocrine cells, coexpressed NKX2.2 but were largely negative for NKX6.1, a sign of immaturity ([Figure S1](#mmc1){ref-type="supplementary-material"}). The differentiated cells were ∼80% PDX1+, ∼50% NKX6.1+, ∼18% PAX6+, and ∼15% Ki67+ ([Figure S1](#mmc1){ref-type="supplementary-material"}). Pluripotent cells (OCT3/4+) were not detected in the differentiated population at the time of transplantation ([Figure S1](#mmc1){ref-type="supplementary-material"}). This preparation of pancreatic progenitor cells was then transplanted under the kidney capsule of either SCID-beige mice (∼5 million cells) or nude rats (∼7 million cells). To determine whether increasing the number of transplanted cells would affect maturation in vivo, we also compared glucose-stimulated human C-peptide secretion at 28 weeks following transplantation of either 5, 10, or 20 million hESC-derived progenitor cells in a separate study ([Figure S2](#mmc1){ref-type="supplementary-material"}). Although the amount of human C-peptide tended to increase with the higher doses of cells, the degree of glucose-responsiveness (indicated by the C-peptide stimulation index) of hESC-derived cells did not differ between doses ([Figure S2](#mmc1){ref-type="supplementary-material"}).

At the time of transplantation, nude rats weighed ∼ ten times more than SCID-beige mice on average ([Figure S3](#mmc1){ref-type="supplementary-material"}A), but rats were transplanted with less than two times the amount of cells ([Figure S3](#mmc1){ref-type="supplementary-material"}B). Therefore, although the kidney grafts in rats were slightly larger than in mice ([Figures S3](#mmc1){ref-type="supplementary-material"}C and S3E), they were not scaled proportionately relative to the profound difference in body weight and, consequently, blood volume of the host ([Figure S3](#mmc1){ref-type="supplementary-material"}D). Interestingly, despite this discrepancy in dosing, plasma human C-peptide concentrations were indistinguishable between species after a meal challenge ([Figure 1](#fig1){ref-type="fig"}A). However, rats had significantly lower basal human C-peptide levels compared with mice between 19 and 32 weeks post-transplantation ([Figure 1](#fig1){ref-type="fig"}A), which translated into an improved stimulation index for meal-induced human C-peptide secretion ([Figure S4](#mmc1){ref-type="supplementary-material"}). At just 19 weeks, hESC-derived cells from rats secreted significantly more human C-peptide under fed versus fasted conditions, whereas there was no meal response by engrafted cells in mice at any stage ([Figure 1](#fig1){ref-type="fig"}A; [Figure S4](#mmc1){ref-type="supplementary-material"}). Blood glucose levels were similar between species after an overnight fast, but mice had consistently higher glucose excursions following a meal compared with rats at all ages examined, regardless of graft maturity ([Figure 1](#fig1){ref-type="fig"}B). Mice also experienced significantly higher glucose excursions during an oral glucose challenge relative to rats ([Figure 1](#fig1){ref-type="fig"}C). Glucose-stimulated human C-peptide secretion was observed in rats at 21 weeks post-transplantation, whereas human C-peptide levels dropped below baseline levels following the glucose challenge in mice ([Figure 1](#fig1){ref-type="fig"}D). There was a trend toward lower basal human C-peptide levels after a 6-hr fast in rats compared with mice, although this did not reach statistical significance (p = 0.06; [Figure 1](#fig1){ref-type="fig"}E). Under random-fed conditions, human insulin, glucagon, and GLP-1 levels were all significantly lower in rats relative to mice at 22 or 33 weeks post-transplantation ([Figure 1](#fig1){ref-type="fig"}F).

Kidney Capsule Grafts from Rats Contain More Mature β Cells Than Those Harvested from Mice {#sec2.2}
------------------------------------------------------------------------------------------

At 22/33 weeks post-transplantation, grafts from rats expressed significantly higher levels of mature β cell genes, including *INS*, *NKX6.1*, *MAFA*, *PAX6*, *ABCC8*, *PCSK1*, and *IAPP*, as well as significantly lower levels of the immature pancreatic endocrine marker *NEUROG3* and mature α cell genes, *GCG* and *ARX*, relative to grafts from mice ([Figure 2](#fig2){ref-type="fig"}). Furthermore, grafts from rats contained approximately three times more insulin relative to glucagon immunoreactivity, whereas glucagon immunoreactivity was almost twice as prevalent as insulin in grafts from mice ([Figures 3](#fig3){ref-type="fig"}A and 3C). Glucagon-positive cells in both species uniformly co-expressed the α cell transcription factor ARX ([Figure S5](#mmc1){ref-type="supplementary-material"}A). Relative to the total endocrine area, grafts from rats were ∼40%--50% insulin-positive, whereas grafts from mice were ∼10%--25% insulin-positive ([Figures 3](#fig3){ref-type="fig"}A and 3C). There also appeared to be more pancreatic polypeptide (PP)-positive cells in grafts from rats, although cells expressing PP, somatostatin, or ghrelin were much less prominent and, therefore, not quantified ([Figure S5](#mmc1){ref-type="supplementary-material"}B). At the gene level, there were no differences in *SST* or *PPY* expression between species, but grafts from mice had approximately two times more *GHRL* transcript compared with grafts from rats ([Figure 2](#fig2){ref-type="fig"}). Overall, hESC-derived progenitor cells developed more efficiently into the endocrine lineage in rats compared with mice, as indicated by the significantly reduced trypsin-positive area ([Figures 3](#fig3){ref-type="fig"}B and 3D), higher proportion of synaptophysin:trypsin immunoreactivity ([Figures 3](#fig3){ref-type="fig"}B and 3D), and decreased gene expression of the exocrine marker *PTF1A* in grafts from rats versus mice ([Figure 2](#fig2){ref-type="fig"}). The presence of non-endodermal germ layers was not detected in kidney capsule grafts from either species ([Table S1](#mmc1){ref-type="supplementary-material"}), unlike grafts generated with our earlier differentiation protocol that, on occasion, contained regions of bone and cartilage tissues ([@bib33]). However, ducts associated with mucin and goblet cells, which are atypical of pancreatic duct morphology, were detected in several grafts from both species ([Table S1](#mmc1){ref-type="supplementary-material"}). The independent pathology analysis is provided in [Table S1](#mmc1){ref-type="supplementary-material"}.

Because the higher levels of mature β cell genes in grafts from rats may simply reflect the higher proportion of β cells, we next examined protein expression for a range of mature β cell markers to assess the maturation status of individual hESC-derived insulin-positive cells. Expression of the β cell transcription factors PDX1, NKX6.1, and NKX2.2 was similar between species ([Figure 4](#fig4){ref-type="fig"}A). However, MAFA expression was highly heterogenous in grafts from mice, ranging from weak or absent to strong nuclear immunoreactivity within the insulin-positive cell population ([Figure 4](#fig4){ref-type="fig"}B, white arrows). In contrast, MAFA immunoreactivity was consistently robust and nuclear within insulin-positive cells in grafts from rats, which supports the observed ∼8-fold increase in *MAFA* gene levels in grafts from rats compared with mice ([Figure 2](#fig2){ref-type="fig"}). Thyroid hormone was recently reported to be a physiological stimulus for β cell maturation in neonatal rats and to regulate *Mafa* expression ([@bib1]). Interestingly, we found that endogenous total triiodothyronine (T3, active thyroid hormone) levels were more than twice as high in rats than in mice at 22 weeks post-transplantation (mice, 0.761 ± 0.11 ng/ml; rats, 1.84 ± 0.15 ng/ml; n = 6/species).

SERPINB2 (serpin peptidase inhibitor, clade B \[ovalbumin\], member 2) and DGCR2 (DiGeorge syndrome critical region gene 2) were recently reported to be unique markers of mature β cells ([@bib22]). We observed robust SERPINB2 and DGCR2 immunoreactivity in adult human β cells and grafts from rats compared with heterogenous expression in both immature human fetal β cells and grafts from mice ([Figure S6](#mmc1){ref-type="supplementary-material"}). Another feature of mature β cells is the presence of prohormone convertase enzymes, which convert proinsulin into mature insulin and C-peptide ([@bib2]). *PCSK1* gene expression was significantly higher in grafts from rats compared with mice ([Figure 2](#fig2){ref-type="fig"}), and almost all engrafted insulin-positive cells coexpressed PC1/3 in rats ([Figure 5](#fig5){ref-type="fig"}). Proinsulin immunoreactivity in grafts from rats was also uniformly punctate and perinuclear ([Figure 5](#fig5){ref-type="fig"}), suggesting that non-processed proinsulin is localized within the *trans*-Golgi network, as expected in human β cells ([@bib2]). In contrast, engrafted insulin-positive cells in mice contained highly heterogenous and generally weaker coexpression of PC1/3, which resulted in diverse patterns of proinsulin immunoreactivity, including cells with intense perinuclear and/or cytoplasmic immunoreactivity ([Figure 5](#fig5){ref-type="fig"}). Collectively, graft analysis indicates that hESC-derived progenitor cells developed into a more mature pancreatic endocrine phenotype in rats compared with mice, with a bias toward the development of β cells instead of α cells.

Grafts from Rats Are Better Vascularized and Express Higher Levels of Genes Involved in Extracellular Matrix Organization Than Grafts from Mice {#sec2.3}
-----------------------------------------------------------------------------------------------------------------------------------------------

Since vascularization is a critical factor for islet graft survival and function post-transplantation ([@bib32]), we measured a panel of secreted human proteins related to angiogenesis. Mice had significantly higher circulating levels of human vascular endothelial growth factor C (VEGF-C) and basic fibroblast growth factor (bFGF) than rats, but all other angiogenic proteins were similar between species ([Figure 6](#fig6){ref-type="fig"}A). Interestingly, we also observed a clear increase in the density and distribution of red blood cells in grafts from rats compared with mice ([Figure 6](#fig6){ref-type="fig"}B; red blood cell area as percent of total graft area; mice, 0.95% ± 0.33%; rats, 4.44% ± 1.40%), suggesting that hESC-derived grafts were better vascularized in rats. Lectins (e.g., wheat germ agglutinin \[WGA\]) are carbohydrate-binding proteins commonly used for marking vasculature ([@bib17], [@bib36]). Substantial lectin staining was observed in grafts from mice and rats, indicating that both were highly vascularized, but lectin staining was noticeably increased within insulin-positive, islet-like structures in grafts from rats ([Figure 6](#fig6){ref-type="fig"}C).

To investigate other pathways that may be involved in promoting β cell maturation in rats, we performed an unbiased gene chip analysis of hESC-derived graft tissue from both species at 22 weeks post-transplantation. Notably, these data revealed robust upregulation of genes related to extracellular matrix (ECM) structure and organization in grafts from rats compared with mice ([Figure 7](#fig7){ref-type="fig"}A). For example, five genes from the collagen family (*COL3A1*, *COL1A1*, *COL15A1*, *COL6A3*, and *COL1A2*) were all upregulated more than 13-fold in grafts from rats compared with mice, along with genes such as *LUM* (lumican), *VCAN* (versican), *FBN1* (fibrillin 1), and *DCN* (decorin), which all encode for important structural components of the ECM ([Figure 7](#fig7){ref-type="fig"}A). A list of genes that were significantly enriched \>5-fold in mouse grafts relative to rat grafts is provided in [Table S2](#mmc1){ref-type="supplementary-material"}. To further investigate the observed changes in ECM-related genes, we next examined circulating levels of human matrix metalloproteinases (MMPs), which are involved in matrix remodeling. Interestingly, at both 22 and 33 weeks post-transplantation, rats had significantly higher plasma levels of human MMP1 and reduced MMP3 levels compared with mice ([Figure 7](#fig7){ref-type="fig"}B). MMP9 levels were not different between species (data not shown). Masson's trichrome staining of engrafted cells confirmed that there were clear differences in the ECM between species ([Figure 7](#fig7){ref-type="fig"}D). Grafts in rats were supported by a highly dense collagen layer on the outer surface of the kidney capsule as well as a compact collagen network intricately embedded throughout the hESC-derived cells, whereas grafts in mice contained less collagen overall, and the collagen network was much looser and stained lighter ([Figure 7](#fig7){ref-type="fig"}D). Masson's trichrome staining of adult human pancreas tissue demonstrated that human islets are normally supported by a complex collagen matrix both on the periphery and also embedded throughout the islet core ([Figure 7](#fig7){ref-type="fig"}C).

Metal-binding metallothioneins (*MT1G*, *MT1X*, and *MT2A*) were also robustly upregulated in grafts from rats compared with mice ([Figure 7](#fig7){ref-type="fig"}A). In rodent and human β cell lines (INS1 and EndoC-βH1, respectively), we found that *MT1* expression was profoundly upregulated in response to cellular stress, including exposure to interleukin 1β (IL-1β) alone, a cytokine cocktail (tumor necrosis factor α \[TNFα\], IL-1β, and interferon γ \[IFNγ\]), or H~2~O~2~ ([Figure S7](#mmc1){ref-type="supplementary-material"}A). To determine whether engrafted cells from mice and rats produced different cytokine profiles, we measured a panel of human cytokines in the circulation at 22 and 33 weeks post-transplantation. Interestingly, most of the cytokines measured were near or below the limit of detection, including MIP1β, MCP-1, MCP-4, IP-10, thymus- and activation-regulated chemokine (TARC), Eotaxin, Eotaxin-3, and macrophage-derived chemokine (MDC) ([Figure S7](#mmc1){ref-type="supplementary-material"}B). In contrast, human IL-8 levels were well into the linear detection range of the assay for the majority of samples and were significantly higher in mice compared with rats ([Figure S7](#mmc1){ref-type="supplementary-material"}B).

Discussion {#sec3}
==========

Following transplantation into immunodeficient mice, immature hESC-derived pancreatic progenitor cells develop over a lengthy maturation period into glucose-responsive, insulin secreting cells ([@bib33], [@bib4]), although this process remains poorly understood. The aim of this study was to determine whether the host species affects the development of hESC-derived progenitor cells in vivo. Interestingly, cells engrafted into nude rats secreted human C-peptide in response to both meal and glucose challenges at a much earlier time compared with cells transplanted into SCID-beige mice. Furthermore, grafts from rats contained a significantly higher proportion of mature β cells, increased expression of ECM-related genes, a more complex collagen matrix, and improved vascularization compared with grafts from mice. These data confirm our previous observation that hESC-derived, insulin-secreting cells were glucose-responsive after a relatively short (14-week) maturation period in nude rats ([@bib33]), and our head-to-head comparison of mice versus rats indicates that this accelerated maturation can likely be attributed to environmental factors within the host milieu.

Based largely on evidence from preclinical studies in immunodeficient mice ([@bib20], [@bib19], [@bib33], [@bib34], [@bib4], [@bib27]), the safety of hESC-derived pancreatic progenitor cells is now being evaluated clinically in a small cohort of patients with type 1 diabetes. However, ongoing preclinical studies in rodent models are still necessary to predict how progenitor cells may behave in a widely variable patient population. Although rats are not an ideal model for humans, their physiology is reportedly more similar to humans than mice ([@bib9]). Blood glucose levels in healthy humans typically range from 4.4--6.1 mM and can rise to nearly 7.8 mM after a full meal ([@bib15]). Similarly, nude rats in our study had fasting blood glucose levels of between ∼3--5 mM and an average peak of 5.5 or 6.7 mM following a meal or glucose challenge, respectively. Unlike humans and rats, SCID-beige mice had relatively high fasting glucose levels (average of 7.2 mM) and dramatic glucose fluctuations peaking at 10 or 18 mM, on average, following a meal or glucose challenge, respectively.

Another advantage of moving to a larger model is the insight gained into scaling up cell dosing to accommodate a larger transplant recipient. Our studies revealed that the dose of pancreatic progenitor cells does not need to be scaled proportionately with body size to produce therapeutic levels of human insulin. Rats received less than two times the amount of cells despite having approximately ten times the blood volume of mice, and, yet, circulating human C-peptide levels were similar between species. Importantly, the grafts did not simply expand to accommodate the larger host but, rather, matured into better functioning β cells compared with the smaller host. We also confirmed in a separate study, that implanting higher numbers of progenitor cells itself does not affect the glucose responsiveness of hESC-derived insulin-secreting cells post-transplantation. Another consideration for predicting cell dosages in humans is that rodents are relatively insensitive to human insulin ([@bib31]), meaning that fewer human progenitor cells may be required per unit of body weight to reverse diabetes in patients compared with rodent models. For instance, although diabetic mice typically require 2,000--4,000 human islet equivalents (IEQs) to achieve normoglycemia (∼80,000--160,000 IEQs/kg), human patients typically require only ∼5,000--10,000 IEQs/kg ([@bib11]). Taken together, these data suggest that the dose of hESC-derived progenitor cells required for humans might be lower than previously predicted based on mouse models.

The fate of hESC-derived pancreatic progenitor cells differed substantially following transplantation in SCID-beige mice versus nude rats. As early as 19 weeks post-transplantation, rats had significantly lower fasting human C-peptide levels and enhanced meal- and glucose-responsive C-peptide secretion compared with mice. One possibility is that the accelerated maturation was driven by differences in immune competence between the two rodent strains. SCID-beige mice possess two autosomal recessive mutations (SCID \[*Prkdc*^scid^\] and beige \[*Lyst*^bg^\]) that result in lack of B and T lymphocytes as well as defective natural killer (NK) cells ([@bib24]), whereas the athymic Rowett nude (RNU) rat is deficient only in T lymphocytes ([@bib6]). Interestingly, when fetal lung xenografts were implanted under the kidney capsule of SCID-beige mice versus nude rats, there were increased inflammation and signs of graft rejection by 4 weeks post-transplantation in nude rats, and the authors speculated that this was likely because of the presence of NK cells in nude rats ([@bib10]). In contrast, pancreatic progenitor cells thrived in nude rats for up to 33 weeks in our study despite the presence of NK cells. Others have also shown that hESC-derived progenitor cells matured similarly in different strains of immunodeficient mice, including B6-TCRα^−/−^ (nonfunctional T cells), B6-RAG^−/−^ (nonfunctional T/B cells), non-obese diabetic (NOD)-SCID (nonfunctional T/B cells and impaired NK cells), and NOD-SCID γ (NSG) mice (nonfunctional T/B cells and nonfunctional NK cells) ([@bib40]), suggesting that the immune competency of the different strains may not have been a critical factor in our study. Another possibility is that exposure to high glucose concentrations may have contributed to high basal insulin production by grafts from mice. Human β cells exposed to high glucose become more active under low-glucose conditions (elevated basal biosynthesis and secretion of insulin) and lose the ability to respond to acute variations in glucose concentrations ([@bib23]). These data are also supported by our previous observations that mice with chronic hyperglycemia had higher basal human C-peptide production by hESC-derived cells compared with normoglycemic mice ([@bib4]).

Rat grafts not only contained a higher proportion of insulin-secreting cells but also a more consistently mature β cell phenotype compared with mice, particularly for immunoreactivity of MAFA, a key transcription factor that regulates glucose-stimulated insulin secretion ([@bib25], [@bib43], [@bib41]), and PC1/3, the dominant prohormone convertase responsible for proinsulin processing ([@bib44]). Indeed, proinsulin immunoreactivity was uniformly restricted to a perinuclear location in grafts from rats as well as human pancreas ([@bib2]), indicating efficient human proinsulin processing, whereas grafts from mice contained irregular patterns of proinsulin immunoreactivity. Because *Mafa* is involved in regulating *Pcsk1* expression ([@bib41]), these differences may be a reflection of the improved *MAFA* gene expression and nuclear MAFA immunoreactivity in β cells from grafts in rats compared with mice. Thyroid hormone has been recently proposed as a physiological regulator of β cell maturation in neonatal rats via Mafa activation ([@bib1]), and addition of T3 during late stages of hESC differentiation induces *MAFA* expression in vitro ([@bib35]). Interestingly, the improved graft function and MAFA levels in nude rats were associated with significantly higher circulating thyroid hormone levels. Therefore, future studies should investigate how modulating thyroid hormone levels in vivo may affect the maturation of hESC-derived β cells.

We performed an unbiased gene profile of immature grafts from mice versus mature grafts from rats at 22 weeks post-transplantation to uncover other pathways associated with improved human β cell maturation in vivo. The most striking finding was that grafts from rats were dramatically enriched for genes related to the structural stability of the ECM, including numerous collagens (*COL3A1*, *COL1A1*, *COL15A1*, *COL6A3*, and *COL1A2*), lumican, versican, and others. We also noted a dramatic, ∼25-fold increase in *SPARC,* a gene that encodes a matricellular protein involved in mediating the interaction between cells and the ECM via regulation of collagen ([@bib3]), in grafts from rats compared with mice. Interestingly, *SPARC* gene expression has been strongly associated with the degree of glucose-stimulated insulin secretion in isolated human islets, and overexpression of *SPARC* in cultured rat β cells enhanced glucose-stimulated insulin secretion ([@bib13]). There is also substantial evidence that reconstructing the islet cell-ECM relationship following islet isolation improves cell survival and function both in vitro and following islet transplantation in vivo ([@bib28], [@bib12], [@bib18], [@bib29], [@bib38], [@bib16], [@bib42]). For example, islets embedded within a collagen matrix displayed enhanced glucose-stimulated insulin secretion ([@bib28], [@bib16], [@bib42]). Similarly, hESC-derived cells with glucose-responsive insulin secretion in rats were embedded in a far more dense and elaborate collagen network compared with the non-responsive insulin-secreting cells in mice. Although these data suggest an association between improved human β cell maturation and the composition of the ECM in the host, it still remains to be determined whether the increased ECM network within rats was a causal factor driving the maturation of hESC-derived β cells.

Our gene chip analysis also revealed a robust upregulation of metallothionein (MT) family members that are involved in metal metabolism and detoxification, as well as reactive oxygen species (ROS) scavenging. Overexpression of MT has been shown to protect mice from streptozotocin (STZ)-induced β cell damage and diabetes ([@bib7]) and to improve islet graft survival following transplantation by protecting islets from hypoxia ([@bib21]). Therefore, the robust induction of MT1/2 in grafts from rats may have contributed to the improved function of hESC-derived β cells by providing protection from the generally hypoxic transplant environment. Engrafted endocrine cells were more highly vascularized in rats than in mice, which may also contribute to protecting the developing β cells from hypoxia and providing more rapid delivery of nutrients for promoting secretagogue-induced secretory responses. We also demonstrated that *MT1* expression is highly inducible in rodent and human β cell lines by various cell stress pathways, including exposure to ROS or cytokines. Interestingly, ROS stimulation has been shown recently to enhance β cell differentiation in pancreatic explants ex vivo, and reducing ROS production in vivo resulted in decreased β cell differentiation ([@bib14]). Grafts from mice produced ∼6-fold more IL-8 than rats, a proinflammatory cytokine that is highly secreted from human islets after culture and into the serum of human islet transplant recipients ([@bib8]). Notably, peri-transplantation administration of reparixin (an IL-8 receptor inhibitor) improved islet graft function and survival in both mice and humans ([@bib8]). Therefore, reducing IL-8 secretion by hESC-derived grafts or preventing IL-8 action post-transplantation may be beneficial to progenitor cell development.

Taken together, these studies provide several clues for understanding the accelerated development of hESC-derived, glucose-responsive β cells within rats, including improved integration of the ECM and vasculature with engrafted cells; induction of metallothionein proteins as a protective response to cellular stress; exposure to lower circulating glucose levels in vivo; higher endogenous thyroid hormone levels, which may contribute to induction of MAFA; and reduced IL-8 secretion by grafts. Clearly further work is required to elucidate the exact mechanism(s) underlying the in vivo development of hESC-derived β cells. These studies also highlight the susceptibility of pancreatic progenitor cells to variation within the host environment. Implantation of progenitor cells into closely related but different species revealed substantial differences in the fate choice between pancreatic endocrine versus exocrine lineages as well as α versus β cell lineages. Because the maturation environment may differ amongst human recipients, future studies should continue to investigate the role of host physiology on progenitor cell differentiation and function following transplantation. Efforts to generate bona fide mature human β cells in vitro ([@bib30], [@bib35], [@bib37]) should also be pursued to minimize the maturation window required in vivo.

Experimental Procedures {#sec4}
=======================

In Vitro Differentiation of hESCs {#sec4.1}
---------------------------------

The H1 hESC line was obtained from the WiCell Research Institute. All experiments at the University of British Columbia (UBC) with H1 cells were approved by the Canadian Stem Cell Oversight Committee and UBC Clinical Research Ethics Board. H1 cells were cultured and differentiated according to our previously published 14-day, four-stage protocol ([@bib4]). Pancreatic progenitor cell quality was assessed by fluorescence-activated cell sorting (FACS) prior to transplantation, as described previously ([@bib33]). Details about FACS antibodies are provided in [Table S3](#mmc1){ref-type="supplementary-material"}.

Animal Studies {#sec4.2}
--------------

All experiments were approved by the UBC Animal Care Committee. Male 8- to 10-week-old SCID-beige mice (C.B-*Igh*-1b/GbmsTac-*Prkdc*^scid^*-Lyst*^bg^N7, Taconic) and male 8- to 10-week-old nude rats (Crl:NIH-*Foxn1*^rnu^, Charles River Laboratories) were maintained on a 12-h light/dark cycle with ad libitum access to a standard irradiated diet (Teklad diet no.2918, Harlan Laboratories).

### Transplantation of hESC-Derived Pancreatic Progenitor Cells {#sec4.2.1}

Animals were anesthetized with inhalable isoflurane and received transplants of hESC-derived pancreatic progenitor cells under the left kidney capsule. For the dose-response study ([Figure S2](#mmc1){ref-type="supplementary-material"}), mice received either 5, 10, or 20 million cells (n = 5--6/group). For the mouse versus rat study, 5 million cells were transplanted into SCID-beige mice (n = 12) and 7 million cells into rats (n = 12) on the same day. Pancreatic progenitor cells were generated from the same differentiation experiment ([Figure S1](#mmc1){ref-type="supplementary-material"}) and divided between the transplant recipients. Progenitor cell clusters were drawn up into PE50 tubing (Intramedic polyethylene tubing, BD Biosciences, catalog no. 427411) using a mechanical micromanipulator. The tubing was sealed with Ligaclips (Ethicon Endo-Surgery, catalog no. LT200) and then spun to pack cells into a compact pellet for transplantation (see [Figure S3](#mmc1){ref-type="supplementary-material"}B for the pelleted cell length). All animals received a single subcutaneous (s.c.) injection of enrofloxacin (Baytril) at the time of transplantation (10 mg/kg, Bayer Animal Health).

### In Vivo Assessment of Transplanted Cells {#sec4.2.2}

All metabolic analyses were performed in conscious, restrained mice and rats. Blood glucose was tested using a handheld glucometer (Lifescan), and all blood samples were collected via the saphenous vein using heparinized microhematocrit tubes. Meal challenges were performed between 4--32 weeks post-transplantation, during which blood was collected after an overnight fast (16 hr) and a subsequent 45-min feeding period with normal chow. An oral glucose tolerance test (OGTT) was performed at 21 weeks post-transplantation. Animals received an oral bolus of glucose (2 g/kg, Vétoquinol) following a 6-hr morning fast. Cardiac blood was collected at 22 weeks (n = 6/species) and 33 weeks (n = 4--5/species) and stored at −30°C until use. For the dose-response study, blood was collected after an overnight fast and 60 min following an intraperitoneal (i.p.) glucose injection (2 g/kg) at 28 weeks post-transplantation.

Cell Culture {#sec4.3}
------------

The INS-1 rat insulinoma cell line and EndoC-βH1 human β cell line (provided by Drs. R Scharfmann, and P. Ravassard) were cultured as described in the [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}. INS-1 and EndoC-βH1 cells were exposed to the following treatments in their respective culture media: 10 ng/ml IL1β alone, cytokine cocktail (10 ng/ml TNF-α \[R&D Systems\], 10 ng/ml IL1β \[Sigma-Aldrich\], and 10 ng/ml IFNγ \[R&D Systems\]), 200 μM H~2~O~2~ (Sigma Aldrich), and 0.5 mM palmitate (sodium salt, Sigma Aldrich). Palmitate was solubilized in 90% ethanol, heated to 60°C, and used in a 1:100 dilution in culture medium supplemented with fatty acid-free 0.5% BSA (Roche Diagnostics).

Multiplex Assay and ELISA {#sec4.4}
-------------------------

Human C-peptide was measured by ELISA in plasma collected during oral meal or glucose challenges (catalog no. 80-CPTHU-E01.1, Alpco Diagnostics). Secreted proteins from the engrafted cells were measured in cardiac plasma with multiplex assays (Mesoscale Discovery), including human angiogenesis markers (catalog no. K15190D-1), human chemokines (catalog no. K15001C-1), human matrix metalloproteinases (catalog no. K15034C-1), human insulin, glucagon, and GLP-1 (catalog no. K15160C-1). Total triiodothyronine levels were measured in cardiac plasma by ELISA (Total T3, catalog no. 1700; Alpha Diagnostic International). All assays were performed according to the manufacturer's instructions.

Histology and Immunofluorescent Staining {#sec4.5}
----------------------------------------

Engrafted kidneys were harvested at 22 weeks post-transplantation (n = 3/species) and processed for paraffin sectioning as described previously ([@bib2]). H&E and Masson's trichrome staining were performed using standard protocols and scanned using a ScanScope CS system (Aperio). H&E-stained kidney grafts were analyzed by an independent pathologist for the presence of non-pancreatic tissue and teratoma formation (Wax-it Histology Services; [Table S1](#mmc1){ref-type="supplementary-material"}). Immunofluorescent staining and imaging were performed as described previously ([@bib2]). Antibody information is provided in [Table S4](#mmc1){ref-type="supplementary-material"}. Vasculature was visualized by staining with lectin (WGA, catalog no. W11261, Life Technologies), which binds to sialic acid and *N*-acetylglucosaminyl residues. Quantification of graft immunoreactivity is described in the [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}. Human fetal pancreas (gestational week 13) was collected according to protocols approved by the Health Sciences Research Ethics Board at the University of Western Ontario. Adult human pancreas tissue was provided by the Irving K. Barber Human Islet Isolation Laboratory with consent to use it for research purposes.

RNA Analysis {#sec4.6}
------------

At 22 weeks (n = 3/species) or 33 weeks (n = 4--5/species) post-transplantation, graft tissue was trimmed from the kidney of a subset of animals and stored in RNA*later* (Life Technologies) at −30°C. RNA was isolated, and gene expression was assessed by real-time PCR with custom Taqman arrays (Applied Biosystems) as described previously ([@bib33]). Details about RNA isolation from INS1 and EndoC-βH1 cells and subsequent qPCR analysis are described in the [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}. Human islets from a 58-year-old, non-diabetic female were used as a positive control. Data were normalized to an internal housekeeping gene (*GAPDH*) using the ΔΔCt method. Information regarding primers is provided in [Table S5](#mmc1){ref-type="supplementary-material"}.

Genome-wide analysis was performed on grafts at 22 weeks post-transplantation using the Affymetrix HG U133+ PM array strip (Affymetrix, catalog no. PN 901569). Details about gene chip analysis are provided in the [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Statistical Analysis {#sec4.7}
--------------------

All statistics were performed using GraphPad Prism software. Specific statistical tests for each experiment are described in the figure legends. For all analyses, p \< 0.05 was considered statistically significant. For area under curve analysis, y = 0 was considered the baseline. All data are presented as mean ± SEM with individual biological replicates shown as separate data points.
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![Improved Glycemic Control and Better Graft Function in Rats Compared with Mice\
(A and B) Human C-peptide (A) and blood glucose levels (B) after an overnight fast and 45 min following an oral mixed meal between 9--32 weeks post-transplantation (n = 4--11 animals/group). ^∗^p \< 0.05, paired t test (fast versus fed); \#p \< 0.05, one-way ANOVA with Student-Neuman-Keuls (SNK) test.\
(C--E) Blood glucose (C) and human C-peptide levels (D and E) following a 6-hr morning fast and subsequent oral glucose challenge at 21 weeks post-transplantation (n = 10--11 animals/group). Human C-peptide levels are presented as (D) fold change relative to basal (red dashed line) or (E) raw values at time 0. For line graphs, ^∗^p \< 0.05, two-way repeated-measures ANOVA with Sidak post hoc test (mouse versus rat). For area under the curve, ^∗^p \< 0.05, ^∗∗∗^p \< 0.001; two-tailed t test.\
(F) Plasma human insulin, glucagon, and GLP-1 levels at 22 or 33 weeks post-transplantation (n = 10 animals/group). The black dashed line indicates the lower limit of detection for each analyte. ^∗∗^p \< 0.01, two-tailed t test.\
Data are presented as mean ± SEM plus individual biological replicates in bar graphs. See [Figure S4](#mmc1){ref-type="supplementary-material"} for the human C-peptide stimulation index following meal challenges.](gr1){#fig1}

![Grafts from Rats Expressed Higher Levels of Mature β Cell Genes and Reduced Pancreatic α and Exocrine Cell Markers Compared with Mice\
Relative gene expression (normalized to adult human islets) of pancreas-related genes in hESC-derived engrafted cells harvested at 22 or 33 weeks post-transplantation (n = 7--8 animals/group). ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, two-tailed t test (mouse versus rat). Data are presented as mean ± SEM plus individual biological replicates.](gr2){#fig2}

![Grafts from Rats Contained a Higher Proportion of Insulin:Glucagon and Synaptophysin:Trypsin Immunoreactivity Compared with Grafts from Mice\
(A and B) Representative immunofluorescence images of whole hESC-derived grafts (graft and kidney tissue is delineated by a dashed white line; scale bars, 500 μm) and higher-magnification insets (scale bars, 100 μm) at 22 weeks post-transplantation. Shown are (A) insulin (red) and glucagon (green) and (B) synaptophysin (red, endocrine marker) and trypsin (green, exocrine marker). DAPI nuclear staining is shown in gray in all images.\
(C) Area of insulin (ins) or glucagon (gcg) immunoreactivity relative to total synaptophysin immunoreactivity and insulin+ area relative to glucagon+ area for each graft.\
(D) Area of synaptophysin or trypsin immunoreactivity relative to the total graft area and synaptophysin+ area relative to trypsin+ area for each graft.\
^∗^p \< 0.05, ^∗∗^p \< 0.01; two-tailed t test. All data are presented as mean ± SEM plus individual biological replicates (n = 3 animals/group). See [Figure S5](#mmc1){ref-type="supplementary-material"} for additional immunofluorescent staining of hESC-derived grafts.](gr3){#fig3}

![hESC-Derived Insulin-Positive Cells from Both Species Expressed Similar β Cell Transcription Factors Except MAFA Expression Was More Heterogenous in Mice.\
(A) Representative immunofluorescent staining of engrafted cells for insulin (red), glucagon (blue), and various transcription factors (green): PDX1, NKX6.1, and NKX2.2 (scale bars, 100 μm).\
(B) Three different regions of insulin-positive cells (red) from each graft illustrate the heterogeneity in nuclear MAFA expression (green; white arrows show examples of insulin-positive cells without nuclear MAFA immunoreactivity). Scale bars, 50 μm. DAPI nuclear staining is shown in gray.\
See [Figure S6](#mmc1){ref-type="supplementary-material"} for additional immunofluorescent staining of mature β cell markers in hESC-derived grafts.](gr4){#fig4}

![Grafts from Mice Express Less PC1/3 and Inconsistent Proinsulin Immunoreactivity Compared with Rats\
Representative immunofluorescent staining of engrafted cells for insulin (red) and either PC1/3 or proinsulin (green). DAPI nuclear staining is shown in gray. White arrowheads indicate cells that are magnified in the insets on the right. Proinsulin immunoreactivity was almost exclusively punctate and perinuclear in grafts from rats, whereas variable patterns of immunoreactivity were observed in mice. Scale bars represent 100 μm (low-magnification images) and 10 μm (high-magnification insets).](gr5){#fig5}

![Engrafted hESC-Derived Cells Were More Highly Vascularized in Rats than in Mice\
(A) Plasma levels of angiogenesis-related secreted proteins at 22 or 33 weeks post-transplantation (n = 9--11 animals/group). The dashed black line indicates the lower limit of detection on each assay. ^∗∗^p \< 0.01, two-tailed t test. Data are presented as mean ± SEM plus individual biological replicates.\
(B) Examples of autofluorescent red blood cells (green) among hESC-derived, insulin-positive endocrine tissue (red) in grafts from mice and rats at 22 weeks post-transplantation. Scale bars, 100 μm.\
(C) Representative immunofluorescent staining of hESC-derived cells at 22 weeks post-transplantation for insulin (red) and lectin (wheat germ agglutinin, green). DAPI nuclear staining is shown in gray for all images. Kidney and graft tissues are delineated by dashed white lines, and white boxes indicate regions shown at higher magnification below. Scale bars, 200 μm (low-magnification images) and 20 μm (high-magnification insets).](gr6){#fig6}

![Grafts from Rats Were Enriched for Genes Related to Extracellular Matrix Composition and Remodeling and Were Densely Integrated with Collagen Fibers\
(A) List of all genes significantly enriched \>5-fold in grafts from rats relative to mice at 22 weeks post-transplantation based on microarray analysis (n = 3 animals/group).\
(B) Plasma concentration of human MMP1 and MMP3 at either 22 or 33 weeks post-transplantation (n = 4--6 animals/group). ^∗^p \< 0.05, ^∗∗^p \< 0.01; two-tailed t test. Data are presented as mean ± SEM plus individual biological replicates.\
(C) Masson's trichrome staining of adult human pancreas shows blue collagen fibers surrounding a duct (white arrow) and an islet (yellow arrow). Scale bar, 100 μm.\
(D) Masson's trichrome staining of hESC-derived grafts at 22 weeks post-transplantation. Low-magnification images of the whole grafts are shown on the left (scale bars, 500 μm). White dashed lines delineate graft and kidney tissue. White boxes highlight the two regions (R1 and R2) shown at higher magnification to the right (scale bars, 100 μm).\
See also [Figure S7](#mmc1){ref-type="supplementary-material"}.](gr7){#fig7}
